would it be fair to say, page-49

You approach this the wrong way round.

Why do we not have any patents protected at this stage of the game should be your question.


But I do not wish to be drawn into examples of milestone payments given by large companies prior to patent protection as it would be such a lengthy discussion and I feel that I spent enough time on this forum for this weekend.

Please research how companies protect promising research, how DPUs ( discovery performance units ) are treated by GSK within their new approach since 2008 for their innovative programs which was trend setting for the industry.


DPUs are intended to operate like a biotech company housed in a big pharma firm. Much as a biotech gets funded by venture capitalists, a DPU receives an initial bolus of money and then extra cash when certain project goals are met. Each DPU had an initial review after a year of operation and will undergo another review this month, the 18-month check point. The board meets a last time at the three-year mark.

This is something I had to hoped to see developed with GSK and certain funding details to be shared with market.